These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 12749745

  • 1. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 3. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 4. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 5. Abciximab. An updated review of its use in ischaemic heart disease.
    Foster RH, Wiseman LR.
    Drugs; 1998 Oct 01; 56(4):629-65. PubMed ID: 9806109
    [Abstract] [Full Text] [Related]

  • 6. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ, Foster RH.
    Pharmacoeconomics; 1999 Dec 01; 16(6):711-41. PubMed ID: 10724797
    [Abstract] [Full Text] [Related]

  • 7. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 01; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM.
    J Am Coll Cardiol; 2000 Aug 01; 36(2):381-6. PubMed ID: 10933346
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.
    Circulation; 1998 Aug 25; 98(8):734-41. PubMed ID: 9727542
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 13. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 19; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 14. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
    Simoons ML, GUSTO IV-ACS Investigators.
    Lancet; 2001 Jun 16; 357(9272):1915-24. PubMed ID: 11425411
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
    JAMA; 1997 Aug 13; 278(6):479-84. PubMed ID: 9256222
    [Abstract] [Full Text] [Related]

  • 17. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
    Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ, TARGET investigators.
    Lancet; 2002 Aug 03; 360(9330):355-60. PubMed ID: 12241774
    [Abstract] [Full Text] [Related]

  • 18. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F, Bresciani B, La Vecchia L, Favero L, Fontanelli A, Galvani M.
    Ital Heart J Suppl; 2002 May 03; 3(5):544-54. PubMed ID: 12064194
    [Abstract] [Full Text] [Related]

  • 19. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr 03; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.